Debora Malpicci

610 total citations
9 papers, 401 citations indexed

About

Debora Malpicci is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Debora Malpicci has authored 9 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Debora Malpicci's work include Melanoma and MAPK Pathways (6 papers), HER2/EGFR in Cancer Research (3 papers) and Synthesis and biological activity (2 papers). Debora Malpicci is often cited by papers focused on Melanoma and MAPK Pathways (6 papers), HER2/EGFR in Cancer Research (3 papers) and Synthesis and biological activity (2 papers). Debora Malpicci collaborates with scholars based in Italy, United States and Malaysia. Debora Malpicci's co-authors include Gennaro Ciliberto, Rita Mancini, Luigi Fattore, Paolo A. Ascierto, Carlo M. Croce, Giuseppe Roscilli, Luigi Aurisicchio, Alessia Noto, Pierpaolo Coluccia and Claudia De Vitis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Cell Death and Disease.

In The Last Decade

Debora Malpicci

8 papers receiving 400 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Debora Malpicci Italy	7	285	212	126	47	42	9	401
Marie Villedieu France	10	416 1.5×	195 0.9×	151 1.2×	27 0.6×	44 1.0×	10	531
Najah Albadari United States	7	269 0.9×	209 1.0×	119 0.9×	34 0.7×	47 1.1×	16	476
Han Koo South Korea	9	371 1.3×	144 0.7×	122 1.0×	31 0.7×	25 0.6×	16	454
Rocco Sciarrillo Netherlands	11	408 1.4×	236 1.1×	151 1.2×	44 0.9×	89 2.1×	17	584
Radosław Polański United Kingdom	12	428 1.5×	268 1.3×	186 1.5×	43 0.9×	111 2.6×	14	602
Nadia Vié France	7	201 0.7×	105 0.5×	164 1.3×	35 0.7×	54 1.3×	10	362
Saketh S. Dinavahi United States	11	222 0.8×	135 0.6×	136 1.1×	82 1.7×	42 1.0×	17	409
Noélia Che China	7	282 1.0×	167 0.8×	103 0.8×	58 1.2×	44 1.0×	10	424
Chung‐Min Yeh Taiwan	13	310 1.1×	134 0.6×	117 0.9×	39 0.8×	42 1.0×	32	441
Kenta Tsunekuni Japan	8	307 1.1×	258 1.2×	142 1.1×	21 0.4×	36 0.9×	14	434

Countries citing papers authored by Debora Malpicci

Since Specialization

Citations

This map shows the geographic impact of Debora Malpicci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debora Malpicci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debora Malpicci more than expected).

Fields of papers citing papers by Debora Malpicci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debora Malpicci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debora Malpicci. The network helps show where Debora Malpicci may publish in the future.

Co-authorship network of co-authors of Debora Malpicci

This figure shows the co-authorship network connecting the top 25 collaborators of Debora Malpicci. A scholar is included among the top collaborators of Debora Malpicci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debora Malpicci. Debora Malpicci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Fattore, Luigi, Debora Malpicci, Ciro Milite, et al.. (2020). Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization. Cell Communication and Signaling. 18(1). 150–150. 6 indexed citations

Ruggiero, Ciro Francesco, Debora Malpicci, Luigi Fattore, et al.. (2019). ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. Cancers. 11(10). 1425–1425. 22 indexed citations

Fattore, Luigi, Susan Costantini, Debora Malpicci, et al.. (2017). MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 8(13). 22262–22278. 84 indexed citations

Fattore, Luigi, Rita Mancini, Mario Acunzo, et al.. (2016). miR-579-3p controls melanoma progression and resistance to target therapy. Proceedings of the National Academy of Sciences. 113(34). E5005–13. 89 indexed citations

Fattore, Luigi, Mario Acunzo, Giulia Romano, et al.. (2016). Abstract 1070: miR-579-3p is a novel master regulator of melanoma progression and drug resistance in metastatic melanoma. Cancer Research. 76(14_Supplement). 1070–1070.

Fattore, Luigi, Debora Malpicci, Emanuele Marra, et al.. (2015). Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Oncotarget. 6(28). 24823–24841. 25 indexed citations

Fattore, Luigi, Debora Malpicci, Emanuele Marra, et al.. (2015). ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors. Journal of Translational Medicine. 13(S1). 8 indexed citations

Noto, Alessia, Salvatore Raffa, Claudia De Vitis, et al.. (2013). Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells. Cell Death and Disease. 4(12). e947–e947. 130 indexed citations

Noto, Alessia, Claudia De Vitis, Giuseppe Roscilli, et al.. (2013). Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer. Oncotarget. 4(8). 1253–1265. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact